Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development
AV Samarelli, V Masciale, B Aramini, GP Coló… - International journal of …, 2021 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …
Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis
H Cheng, S Jiang, J Cai, Z Luo, X Li… - Frontiers in Cell and …, 2024 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown origin and
the most common interstitial lung disease. However, therapeutic options for IPF are limited …
the most common interstitial lung disease. However, therapeutic options for IPF are limited …
Revealing the mechanism of Jiegeng decoction attenuates bleomycin-induced pulmonary fibrosis via PI3K/Akt signaling pathway based on lipidomics and …
Y Xu, X Wang, D Han, J Wang, Z Luo, T Jin, C Shi… - Phytomedicine, 2022 - Elsevier
Background Pulmonary fibrosis (PF) is a serious lung disease with unknown etiology and
irreversible course. Jiegeng decoction (JGD), a traditional prescription, is widely used to …
irreversible course. Jiegeng decoction (JGD), a traditional prescription, is widely used to …
Hypoxia inducible factor 1A supports a pro-fibrotic phenotype loop in idiopathic pulmonary fibrosis
G Epstein Shochet, B Bardenstein-Wald… - International Journal of …, 2021 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. The
IPF-conditioned matrix (IPF-CM) system enables the study of matrix–fibroblast interplay …
IPF-conditioned matrix (IPF-CM) system enables the study of matrix–fibroblast interplay …
A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
T Imakura, S Sato, K Koyama, H Ogawa, T Niimura… - Respiratory …, 2023 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with few
effective therapeutic options. Recently, drug repositioning, which involves identifying novel …
effective therapeutic options. Recently, drug repositioning, which involves identifying novel …
Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer
X Ji, KP Williams, W Zheng - Cancer Informatics, 2023 - journals.sagepub.com
The aim of this study was to utilize a computational methodology based on Gene Reversal
Rate (GRR) scoring to repurpose existing drugs for a rare and understudied cancer …
Rate (GRR) scoring to repurpose existing drugs for a rare and understudied cancer …
Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508‐CFTR for cystic fibrosis
Rare diseases affect 10% of the first‐world population, yet over 95% lack even a single
pharmaceutical treatment. In the present age of information, we need ways to leverage our …
pharmaceutical treatment. In the present age of information, we need ways to leverage our …
[引用][C] Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past
B Crestani - European Respiratory Journal, 2024 - Eur Respiratory Soc